: Aromatase inhibitors (AIs) frequently lead to the AI-induced musculoskeletal syndrome (AIMSS). Looking into its pathophysiology, 6 months of AI therapy thickens the tendon sheath with intra-articular fluid (IAF) retention and loss of grip strength. We here report 24-month follow-up data.
introduction
In postmenopausal women with a hormone receptor-positive breast cancer, any of the three oral aromatase inhibitors (AIs) in a 5-year adjuvant treatment schedule or sequentially used for 2-3 years with 3-2 years tamoxifen will reduce breast cancer events compared with tamoxifen [1] [2] [3] . This together with a more predictable and according to some, a safer adverse event profile over tamoxifen, has substantially increased the use of AIs. However, the decline in postmenopausal estrogen levels following AI intake is thought to be responsible for the exacerbation of menopause-related symptoms, including musculoskeletal problems that are among the most commonly reported adverse events in most of the large trials [4] [5] [6] [7] . This AI-induced musculoskeletal syndrome (AIMSS) includes arthralgia, joint stiffness, myalgia and carpal tunnel syndrome and has been noted in up to half of the treated patients in daily clinical practice, which is more frequent than previously envisaged in the clinical trials. AIMSS contributes to decreased compliance and provokes treatment discontinuation in up to 25% of the treated patients [8] [9] [10] . To date, the mechanisms underlying the development of this syndrome remain unclear.
Using magnetic resonance imaging (MRI), we previously showed that AIMSS is characterized by tenosynovial changes and increase in intra-articular fluid (IAF) following 6 months of AI treatment. Moreover, morning stiffness and decreased grip strength were important symptoms associated with AIMSS [11, 12] . Other groups using high-resolution ultrasound confirmed these abnormalities of the tendon sheath [13, 14] .
Considerable uncertainty exists regarding the duration of these musculoskeletal events. It has been suggested that arthralgia may be self-limiting with a reduction of severity of symptoms over time [15] although the delayed onset of AIMSS has also been reported [16, 17] . We here compare the already reported 6-month data [12] with findings regarding normal daily functioning and MRI of hands and wrists at 24 months in the same cohort of postmenopausal breast cancer patients treated with an AI or tamoxifen.
patients and methods

design, participants and measurements
We used the same prospective study cohort from University Hospitals Leuven of 33 consecutive postmenopausal women with an early hormone receptor-positive breast cancer planning to start either on an AI (anastrozole, letrozole or exemestane) or on tamoxifen between May 2006 and August 2007. The decision to treat with an AI or tamoxifen was based on our institution's in-house protocol for the use of either therapy; there was no self-selection of patients based on age or pre-existing joint symptoms.
The design and conduct have previously been described [11, 12] . Demographic and rheumatologic history data were collected at baseline together with a clinical examination of both hands by a blinded (to endocrine treatment and MRI findings) rheumatologist. Each patient was carefully assessed by examination of joint and tendon abnormalities and functional evaluation was performed by a hand grip test with a modified sphygmomanometer. The following parameters were evaluated: musculoskeletal pain, morning stiffness, hand stiffness/pain/paresthesia, flexor tendon nodules/contractures/crepitations/pain/trigger phenomenon, osteoarthritis, degenerative joints and synovitis. The Health Assessment Questionnaire (HAQ) was also completed by the patient. Tenosynovial changes and IAF of both hands and wrists were evaluated by MRI. All images were interpreted by a single treatment-blinded, experienced musculoskeletal radiologist. Clinical and radiological follow-up investigations were repeated at 6 and 24 months of therapy.
The results of the rheumatologic examination at 24 months are scored 1 (new onset or worsening of 6 month symptoms), −1 (improvement of 6 month findings or disappearance) or 0 (no change). The changes in grip strength are expressed as the percentage change versus 6 months.
MRI results are reported as the number of images that showed the pathology (there is one image for each hand and thus two images per patient). The repeat MRI at 24 months took into account the 6 months findings. Tenosynovial changes were defined as an increase in the amount of fluid in the tendon sheath or the thickening and enhancement of the tendon sheaths. For tenosynovial abnormalities and IAF, the scores for each hand were as per the rheumatologic examination (−1, 0, 1). Also, a combined score was constructed by summing the scores of both hands. This score could equal -2 (improvement for both hands), -1 (improvement for one hand, no change for the other), 0 (no change for both hands, or improvement for one hand and worsening for the other), +1 (worsening for one hand, no change for the other) and +2 (worsening for both hands).
The study was conducted according to the guidelines for clinical studies described in the Declaration of Helsinki [18] . The protocol was approved by the Ethics Committee for Clinical Studies of the University Hospitals Leuven, Belgium, before the initiation of the study and all participants provided written informed consent.
study end points
The primary end point of this analysis was the change between 6 and 24 months in tenosynovial abnormalities on MRI. Secondary end points were changes over the same time period for morning stiffness, grip strength, IAF on MRI and a number of rheumatologic parameters. We further analyzed the relationship between MRI measurements and grip strength or rheumatologic symptoms. Finally, the quadratic relationship previously identified between grip strength and body mass index (BMI) was evaluated.
statistical analysis
MRI measurements were analyzed to evaluate change versus last observation, resulting in a score with three levels for each hand, and a score with five levels in case of a combined score for both hands. The sign test was used to evaluate changes in tenosynovial abnormalities or IAF, and percentages with 95% confidence intervals for multinomial proportions are reported. Data from subjects who completed all 24 months of initial therapy were included in the analysis. To account for the fact that a worsening condition may precisely have led to drop-out, a sensitivity analysis was carried out, assuming the worst possible score at the 2-year measurement for the dropouts, and results of both analyses were compared.
Rheumatologic parameters were assessed on a three-point scale. For the analysis of change over time a proportional odds model with a subjectspecific random effect to account for the correlation between the measurement coming from the subject was used. To analyze the time trend on these parameters, we used a proportional odds model with random intercept to deal with longitudinal measurements.
Both grip strength and the HAQ were measured on continuous scales. For analyzing the time trend, we used a linear mixed model. For the analysis of grip strength, correlations between both hands were additionally taken into account. The same model was used to analyze the relationship between grip strength and BMI. Both approaches are likelihood-based and therefore valid under the missing-at-random assumption for the drop-outs, which would hold if patients with worse adverse events are more likely to dropout.
To analyze the relationship between MRI measurements and grip strength or symptom measurements (hand stiffness, hand paresthesia and hand pain), we used a proportional odds model with random intercept to account for correlations between the hands within a patient.
For the small group of tamoxifen patients, only summary statistics were carried out.
All analyses have been carried out using the SAS software, version 9. 
patient characteristics
Thirty-one of the 33 included patients completed all the planned investigations. Of these patients, 26 were treated with an AI (letrozole, N = 10, exemestane, N = 9, anastrozole, N = 7) and 5 with tamoxifen. However, three patients in the AI group prematurely discontinued AI treatment; two patients switched to tamoxifen, one due to musculoskeletal problems. The third patient abandoned treatment due to intolerable musculoskeletal pain. Another patient switched from AI treatment to tamoxifenappear. One patient switched from tamoxifen to anastrozole 3 months before the 6-month measurement due to joint problems and is included in the AI group for the 24-month assessment. Baseline demographic and medical characteristics are described in Table 1 ). Previous intake of hormone replacement therapy was comparable in each group. Three patients in the AI group and one in the tamoxifen group received adjuvant chemotherapy before start of endocrine therapy.
Pre-existing rheumatologic disorders, in particular osteoarthritis, were encountered in the majority of patients before start of endocrine therapy. On baseline MRI, fluid accumulation was present in the joints of seven AI users and in two of the tamoxifen patients. Tenosynovial abnormalities were seen in five of the AI users and in two of the tamoxifen patients.
changes in tenosynovium and IAF between 6 months and 2 years Table 2 shows a further statistically significant worsening of IAF between the 6-and 24-month assessments in AI users (P = 0.04); 60% had stable IAF. No evidence was found for a systematic change in tenosynovial abnormalities between 6 months and 2 years (P = 1). 33.4% of the AI patients had a worsening of tenosynovial abnormalities; others either had stable changes (38.1%) or improvement (28.6%). One patient refused the MRI measurements at 24 months. Given that patients with worsening condition may have been more inclined to discontinue the treatment, we carried out a sensitivity analysis, assuming the worst score possible for the three patients who discontinued AI therapy. Still, we did not observe a change in tenosynovial abnormalities, confirming our previous results.
The majority of tamoxifen users showed no change in MRI measurements for either end point. Two of the three patients who switched from AI therapy to tamoxifen before the 2-year measurement showed stable IAF, whereas one patient had worsening of IAF. Tenosynovial abnormalities improved in both hands/wrists in two patients and worsened in the other patient.
changes in grip strength and morning stiffness from 6 months anti-hormonal therapy Significant worsening in grip strength between baseline and 6 months of AI treatment was previously reported [12] . Between 6 months and 2 years, we observed a further decrease in average grip strength of 2.3 kPa (P = 0.19). There was a tendency to have more strength in the right hand (which is more often the dominant hand; Table 1 ).
Patients treated with an AI were characterized by a median reduction in grip strength of 7.1% (range −79.5%; 61.3%) after 2 years in the right hand compared with 6 months and a median decrease of 5.3% (range −85.6%; 57.2%) for the left hand. Tamoxifen patients experienced a median decrease of 6.9% (range −30.2%; −1.5%) in the right hand relative to 6 months and a median decrease of 6.8% (range −21.1%; 0%) in the left hand.
In the three patients that ended their AI treatment (two switched to tamoxifen and one stopped endocrine therapy) more than 1 year before the last observations, grip strength The sign test to test whether there is a significant difference from 0 in the change in tenosynovial abnormalities (P = 1.0) and in intra-articular fluid (P = 0.04) score: −2 (improvement for both hands), −1 (improvement for one hand, no change for the other), 0 (no change for both hands, or improvement for one hand and worsening for the other), +1 (worsening for one hand, no change for the other) and +2 (worsening for both hands). AI, aromatase inhibitor; Tam, tamoxifen; CI, confidence interval.
original articles Annals of Oncology increased in both hands. One patient who complained of substantial hand pain and stiffness during letrozole treatment showed a substantial increase in grip strength of >150% in both hands 1 year after switching to tamoxifen. No morning stiffness was reported in tamoxifen patients, whereas more than one-third of AI users continued to experience morning stiffness (Table 3 ). In the majority of the AI-treated patients, no change in morning stiffness score was reported. Three patients experienced an improvement in morning stiffness, whereas two patients complained of worsening compared with the 6-month assessments. There was no statistically significant change in morning stiffness between 6 and 24 months of follow-up after therapy start (P = 0.45).
In the three patients who switched to tamoxifen, two reported no change in morning stiffness (1 present, 1 absent) and one patient experienced disappearance of morning stiffness.
Improvement was observed between 6 months and 2 years on contractures/crepitations/nodules in the flexor tendons of patients treated with an AI (P = 0.04). Additionally, we observed non-significant improvements at 2 years compared with 6 months on hand stiffness, hand paresthesia, pain in hand or flexor tendons, trigger finger, degenerative joints and synovitis (P > 0.1). Non-significant worsening was observed for general musculoskeletal pain (P = 0.86) and the HAQ (P = 0.1).
association between MRI measurements with change in grip strength and rheumatologic symptoms Worsening of tenosynovial changes at 2 years compared with 6 months, as seen on MRI, was strongly related to a larger decrease in grip strength in AI-and tamoxifen-treated patients (P = 0.009; Table 4 ). No correlation was demonstrated between IAF and change in grip strength (P = 0.86). In addition, no association was detected between MRI measurements and hand pain/stiffness or paresthesias (P = 0.25 and 0.12, respectively, for IAF and P = 0.53 and 0.2, respectively, for tenosynovial changes).
relationship between BMI and grip strength for AI users
To analyze the relationship between grip strength and BMI, a model with hand, grip strength, age, BMI and a quadratic effect for BMI as predictors was used (Table 5) . One patient with BMI of 45 kg/m 2 was a major outlier and was excluded from analysis. A significant quadratic relationship was found between grip strength and BMI, with the worst performances for the extremes in BMI, as we described earlier [12] .
discussion
We previously reported that AI users show increased tenosynovial changes and IAF after 6 months of therapy. Here, in these final 2-year results, we show that IAF further accumulates compared with 6 months after AI start (P = 0.04). Stable or worsened articular changes were observed in 22 of the 23 AI-treated patients.
Additionally, 72% of the patients showed stable or increased tenosynovial abnormalities, as observed on MRI.
The results of the current study are in line with those of Henry and Dizdar [14, 19] , although the latter trial had a cross-sectional design and the group of Henry et al. only had one follow-up ultrasonography per patient. Our long-term observations stress the importance of these musculoskeletal symptoms, proven by their persistence 2 years after start of AI therapy.
Regarding functional evaluation of hands, a further decrease in grip strength between 6-and 24-month measurements was recorded in AI-treated patients. In addition, this decrease in grip strength was strongly correlated with the worsened tenosynovial changes, compared with 6 months, whereas Score tenosynovial changes: −2 (improvement for both hands), −1 (improvement for one hand, no change for the other), 0 (no change for both hands, or improvement for one hand and worsening for the other), +1 (worsening for one hand, no change for the other) and +2 (worsening for both hands). 
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improved tenosynovial abnormalities were associated with increased grip strength in both hands. It should be noted that degenerative joint disease was already present in a majority of the patients at baseline, emphasizing the need to properly identify these complaints before treatment start and to frequently assess them during endocrine therapy.
The discontinuation of AI treatment >1 year before assessment led to an increase in grip strength in three patients (two switched to tamoxifen and one ended endocrine therapy). Furthermore, tenosynovitis was seen on MRI in these patients after 6 months of AI therapy, and this abnormality improved at the 2-year assessment in the two patients who had switched to tamoxifen. Although the number of patients is small, these findings suggest that the AI-induced changes are reversible, at least in a subset of patients.
The quadratic relationship between baseline BMI and change in grip strength seen in the 6-month measurements was confirmed in our 2 years data. Patients with extremes in BMI, very low and very high BMI, are more prone to develop joint problems on AI therapy. This relationship is currently being investigated in a large prospective study in our hospital and in University of Michigan.
The pathogenesis of AIMSS still remains unknown. It is probably related to estrogen deprivation as arthralgia is a common phenomenon in postmenopausal women, initiating during perimenopause. In addition, hormonal substitution therapy (HST) has been shown to improve musculoskeletal symptoms, and estrogens play an important role in the collagen maintenance and modulation of pain perception. Furthermore, a protective effect of estrogen in arthritis and on pro-inflammatory cytokines has been suggested [20] . However, inflammatory or auto-immunity factors do not differ between patients with and without AIMSS [14] . This is in contrast with menopausal arthralgia, where osteoarthritis and cartilage defects are the most encountered problems [21] . Recent use of HST, recent menopause, low BMI and obesity are all risk factors for the development of AIMSS, which can be explained by a decrease in estrogens at start of treatment [17, 22] . When patients were divided into <10 years past menopause and 10 or more years past menopause, we indeed observed a doubling in worsened AI-induced musculoskeletal disorders on MRI in the first group. Several reports showed that AIMSS occurs earlier and is more frequent in younger postmenopausal women [15, 16, 22] , which we confirm in our data. In patients aged 49-58 years (mean 3 years past menopause), 50% experienced a worsening of IAF and/or tenosynovial abnormalities, compared with 20% in the group 60-68 years (mean 11 years past menopause) and 28% in the oldest quartile (70-74 years; mean 24 years past menopause).
Although AIMSS is an important problem only about half of patients develop these musculoskeletal symptoms, suggesting the importance of subtle intra-individual differences. In addition to the clinical factors mentioned above, single nucleotide polymorphisms (SNP's) could be partly responsible for this as demonstrated by several groups [23] [24] [25] [26] . Therefore, we are also screening for SNP's for correlation with estrogen levels and development of AIMSS in our ongoing trial.
A potential limitation of this study is the MRI reproducibility. However, this effect was minimized in this study by having images interpreted by a single musculoskeletal radiologist who was blinded to treatment and clinical data. Another limitation is the small sample size of the tamoxifen group, but only summary statistics were reported for this group.
These results show that most of the patients continue to experience AIMSS 2 years after start of AI therapy, in contrast to the suggestion that arthralgia may be self-limiting with a reduction of severity of symptoms over time. The functional impairment of hands seen in AIMSS patients is characterized by tenosynovial changes on MRI correlating with a significant decrease in hand grip strength.
In addition, AI users showed a further increase in IAF and a decrease in grip strength. This highlights the importance of these musculoskeletal side effects and urges for a further unraveling of the etiology to identify patients at risk and to present effective treatments as this remains disappointing. 
